Hypothyroidism due to deficient transcription factors involved in pituitary development or function

Summary

Hypothyroidism due to deficient transcription factors involved in pituitary development or function (MONDO:0016411) is a disease with 5 cohort genes.

At a glance

• Prevalence: Unknown (Worldwide)
• Cohort genes: 5
• Phenotypes (HPO): 51

Clinical features

Signs & symptoms

Clinical features (HPO)

51 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO ID	Term	Frequency
HP:0008245	Pituitary hypothyroidism	Very frequent (80-99%)
HP:0031098	Decreased thyroid-stimulating hormone level	Very frequent (80-99%)
HP:0031219	Reduced radioactive iodine uptake	Very frequent (80-99%)
HP:0000158	Macroglossia	Frequent (30-79%)
HP:0000270	Delayed cranial suture closure	Frequent (30-79%)
HP:0000282	Facial edema	Frequent (30-79%)
HP:0000871	Panhypopituitarism	Frequent (30-79%)
HP:0001254	Lethargy	Frequent (30-79%)
HP:0001265	Hyporeflexia	Frequent (30-79%)
HP:0001510	Growth delay	Frequent (30-79%)
HP:0001537	Umbilical hernia	Frequent (30-79%)
HP:0001662	Bradycardia	Frequent (30-79%)
HP:0002019	Constipation	Frequent (30-79%)
HP:0002045	Hypothermia	Frequent (30-79%)
HP:0004491	Large posterior fontanelle	Frequent (30-79%)
HP:0005930	Abnormality of epiphysis morphology	Frequent (30-79%)
HP:0005990	Thyroid hypoplasia	Frequent (30-79%)
HP:0006579	Prolonged neonatal jaundice	Frequent (30-79%)
HP:0008202	Reduced circulating prolactin concentration	Frequent (30-79%)
HP:0008828	Delayed proximal femoral epiphyseal ossification	Frequent (30-79%)
HP:0008872	Feeding difficulties in infancy	Frequent (30-79%)
HP:0010627	Anterior pituitary hypoplasia	Frequent (30-79%)
HP:0012378	Fatigue	Frequent (30-79%)
HP:0012758	Neurodevelopmental delay	Frequent (30-79%)
HP:0031507	Decreased circulating thyroxine level	Frequent (30-79%)
HP:0040075	Hypopituitarism	Frequent (30-79%)
HP:0000044	Hypogonadotropic hypogonadism	Occasional (5-29%)
HP:0000407	Sensorineural hearing impairment	Occasional (5-29%)
HP:0000470	Short neck	Occasional (5-29%)
HP:0000609	Optic nerve hypoplasia	Occasional (5-29%)
HP:0000824	Decreased response to growth hormone stimulation test	Occasional (5-29%)
HP:0000839	Pituitary dwarfism	Occasional (5-29%)
HP:0001161	Hand polydactyly	Occasional (5-29%)
HP:0001252	Hypotonia	Occasional (5-29%)
HP:0001274	Agenesis of corpus callosum	Occasional (5-29%)
HP:0001317	Abnormal cerebellum morphology	Occasional (5-29%)
HP:0001943	Hypoglycemia	Occasional (5-29%)
HP:0001999	Abnormal facial shape	Occasional (5-29%)
HP:0002920	Decreased circulating ACTH level	Occasional (5-29%)
HP:0004637	Decreased cervical spine mobility	Occasional (5-29%)
HP:0005280	Depressed nasal bridge	Occasional (5-29%)
HP:0009381	Short finger	Occasional (5-29%)
HP:0011220	Prominent forehead	Occasional (5-29%)
HP:0011755	Ectopic posterior pituitary	Occasional (5-29%)
HP:0011800	Midface retrusion	Occasional (5-29%)
HP:0025502	Overweight	Occasional (5-29%)
HP:0030341	Decreased circulating follicle stimulating hormone concentration	Occasional (5-29%)
HP:0030344	Decreased circulating luteinizing hormone level	Occasional (5-29%)
HP:0031218	Inappropriate antidiuretic hormone secretion	Occasional (5-29%)
HP:0011437	Maternal autoimmune disease	Excluded (0%)

Identifiers

Disease identifiers

Field	Value
Canonical name	hypothyroidism due to deficient transcription factors involved in pituitary development or function
Mondo ID	MONDO:0016411
Orphanet	226307
UMLS	C4273672
MedGen	900830
GARD	0020562
Is cancer (heuristic)	no

Data availability: 5 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › hereditary endocrine growth disease › permanent congenital hypothyroidism › central congenital hypothyroidism › hypothyroidism due to deficient transcription factors involved in pituitary development or function

Related subtypes (4): isolated thyroid-stimulating hormone deficiency, isolated thyrotropin-releasing hormone deficiency, X-linked central congenital hypothyroidism with late-onset testicular enlargement, hypothyroidism, congenital, nongoitrous, 7

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 43 · Orphanet: 17 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
LHX3	Definitive	Autosomal recessive	non-acquired combined pituitary hormone deficiency with spine abnormalities	5
LHX4	Definitive	Autosomal dominant	short stature-pituitary and cerebellar defects-small sella turcica syndrome	8
POU1F1	Definitive	Semidominant	pituitary hormone deficiency, combined, 1	10
PROP1	Definitive	Autosomal recessive	pituitary hormone deficiency, combined, 2	8
HESX1	Strong	Autosomal dominant	combined pituitary hormone deficiencies, genetic form	12

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
LHX4	Orphanet:226307	Hypothyroidism due to deficient transcription factors involved in pituitary development or function
LHX4	Orphanet:85442	Short stature-pituitary and cerebellar defects-small sella turcica syndrome
LHX4	Orphanet:95494	Combined pituitary hormone deficiencies, genetic forms
LHX4	Orphanet:95496	Pituitary stalk interruption syndrome
HESX1	Orphanet:226307	Hypothyroidism due to deficient transcription factors involved in pituitary development or function
HESX1	Orphanet:3157	Septo-optic dysplasia spectrum
HESX1	Orphanet:478	Kallmann syndrome
HESX1	Orphanet:95494	Combined pituitary hormone deficiencies, genetic forms
HESX1	Orphanet:95496	Pituitary stalk interruption syndrome
LHX3	Orphanet:226307	Hypothyroidism due to deficient transcription factors involved in pituitary development or function
LHX3	Orphanet:231720	Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome
POU1F1	Orphanet:226307	Hypothyroidism due to deficient transcription factors involved in pituitary development or function
POU1F1	Orphanet:231679	Isolated growth hormone deficiency type II
POU1F1	Orphanet:95494	Combined pituitary hormone deficiencies, genetic forms
PROP1	Orphanet:226307	Hypothyroidism due to deficient transcription factors involved in pituitary development or function
PROP1	Orphanet:90695	Non-acquired panhypopituitarism
PROP1	Orphanet:95494	Combined pituitary hormone deficiencies, genetic forms

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
LHX4	HGNC:21734	ENSG00000121454	Q969G2	LIM/homeobox protein Lhx4	gencc
HESX1	HGNC:4877	ENSG00000163666	Q9UBX0	Homeobox expressed in ES cells 1	gencc
LHX3	HGNC:6595	ENSG00000107187	Q9UBR4	LIM/homeobox protein Lhx3	gencc
POU1F1	HGNC:9210	ENSG00000064835	P28069	Pituitary-specific positive transcription factor 1	gencc
PROP1	HGNC:9455	ENSG00000175325	O75360	Homeobox protein prophet of Pit-1	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
LHX4	LIM/homeobox protein Lhx4	May play a critical role in the development of respiratory control mechanisms and in the normal growth and maturation of the lung.
HESX1	Homeobox expressed in ES cells 1	Required for the normal development of the forebrain, eyes and other anterior structures such as the olfactory placodes and pituitary gland.
LHX3	LIM/homeobox protein Lhx3	Transcription factor.
POU1F1	Pituitary-specific positive transcription factor 1	Transcription factor involved in the specification of the lactotrope, somatotrope, and thyrotrope phenotypes in the developing anterior pituitary.
PROP1	Homeobox protein prophet of Pit-1	Possibly involved in the ontogenesis of pituitary gonadotropes, as well as somatotropes, lactotropes and caudomedial thyrotropes.

Protein-family classification

Druggable: 0 · Difficult: 5 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	5	8.3×	3e-05

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
LHX4	Transcription factor	no		HD, Znf_LIM, Homeodomain-like_sf
HESX1	Transcription factor	no		HD, Homeodomain-like_sf, Homeobox_CS
LHX3	Transcription factor	no		HD, Znf_LIM, Homeodomain-like_sf
POU1F1	Transcription factor	no		POU_dom, HD, Homeodomain-like_sf
PROP1	Transcription factor	no		HTH_motif, HD, Homeodomain-like_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	1
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adenohypophysis	3
pituitary gland	3
buccal mucosa cell	2
pancreatic ductal cell	1
sperm	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
diaphragm	1
decidua	1
bone marrow cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
LHX4	166	tissue_specific	yes	buccal mucosa cell, sperm, pancreatic ductal cell
HESX1	167	broad	marker	buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
LHX3	22	tissue_specific	yes	pituitary gland, diaphragm, adenohypophysis
POU1F1	73	tissue_specific	yes	pituitary gland, adenohypophysis, decidua
PROP1	4		yes	pituitary gland, adenohypophysis, bone marrow cell

Protein interactions among cohort

Intra-cohort edges: 5.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
LHX3	1,661
LHX4	1,566
POU1F1	1,170
PROP1	1,160
HESX1	888

Intra-cohort edges

A	B	Sources
HESX1	POU1F1	string_interaction
LHX3	LHX4	intact
LHX3	POU1F1	string_interaction
LHX4	POU1F1	biogrid_interaction, intact, string_interaction
POU1F1	PROP1	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
LHX4	Q969G2	1
HESX1	Q9UBX0	1
POU1F1	P28069	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PROP1	O75360	70.74
LHX3	Q9UBR4	68.68

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 5 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by ROBO receptors	2	124.1×	3e-04	LHX4, LHX3
Regulation of expression of SLITs and ROBOs	2	69.2×	5e-04	LHX4, LHX3
Axon guidance	2	45.1×	7e-04	LHX4, LHX3
Nervous system development	2	42.9×	7e-04	LHX4, LHX3
Developmental Biology	2	14.5×	0.005	LHX4, LHX3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
medial motor column neuron differentiation	2	3370.4×	3e-06	LHX4, LHX3
somatotropin secreting cell differentiation	2	1685.2×	1e-05	LHX3, PROP1
regulation of transcription by RNA polymerase II	5	11.7×	7e-05	LHX4, HESX1, LHX3, POU1F1, PROP1
motor neuron axon guidance	2	280.9×	2e-04	LHX4, LHX3
placenta development	2	177.4×	4e-04	LHX4, LHX3
negative regulation of apoptotic process	3	20.9×	0.002	LHX4, LHX3, PROP1
animal organ morphogenesis	2	76.6×	0.002	LHX4, LHX3
apoptotic process	3	17.2×	0.002	LHX4, LHX3, PROP1
hypophysis morphogenesis	1	1685.2×	0.003	PROP1
prolactin secreting cell differentiation	1	1685.2×	0.003	LHX3
neuron differentiation	2	40.1×	0.004	LHX4, LHX3
leukemia inhibitory factor signaling pathway	1	842.6×	0.004	HESX1
hypothalamus cell differentiation	1	674.1×	0.005	PROP1
ventral spinal cord interneuron specification	1	561.7×	0.005	LHX3
thyroid-stimulating hormone-secreting cell differentiation	1	561.7×	0.005	LHX3
adenohypophysis development	1	481.5×	0.005	POU1F1
nose development	1	481.5×	0.005	HESX1
otic vesicle formation	1	421.3×	0.006	HESX1
positive regulation of transcription by RNA polymerase II	3	8.9×	0.006	LHX4, LHX3, POU1F1
spinal cord motor neuron cell fate specification	1	306.4×	0.007	LHX3
forebrain morphogenesis	1	280.9×	0.008	HESX1
spinal cord association neuron differentiation	1	259.3×	0.008	LHX3
gonad development	1	224.7×	0.009	HESX1
cellular response to cadmium ion	1	153.2×	0.012	HESX1
pituitary gland development	1	129.6×	0.014	HESX1
thyroid gland development	1	108.7×	0.016	HESX1
dorsal/ventral pattern formation	1	84.3×	0.019	PROP1
stem cell population maintenance	1	84.3×	0.019	HESX1
blood vessel development	1	74.9×	0.020	PROP1
inner ear development	1	74.9×	0.020	LHX3

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5

Druggability breadth: 0 of 5 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
LHX4	0	0
HESX1	0	0
LHX3	0	0
POU1F1	0	0
PROP1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	LHX4, HESX1, LHX3, POU1F1, PROP1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
LHX4	0	—
HESX1	0	—
LHX3	0	—
POU1F1	0	—
PROP1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.